Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-1, India facility. The inspection for the facility was conducted by the USFDA between February 3, 2020 and February 11, 2020 and concluded with two observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.